Oncothyreon Inc (USA)  

(Public, NASDAQ:ONTY)   Watch this stock  
Find more results for ONTY
1.72
-0.02 (-1.15%)
Apr 17 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.69 - 1.75
52 week 1.48 - 3.60
Open 1.75
Vol / Avg. 600,158.00/823,526.00
Mkt cap 175.96M
P/E     -
Div/yield     -
EPS -0.61
Shares 102.30M
Beta 1.05
Inst. own 54%
Apr 29, 2015
Q1 2015 Oncothyreon Inc Earnings Release (Estimated) Add to calendar
Mar 10, 2015
Q4 2014 Oncothyreon Inc Earnings Call - Webcast
Mar 10, 2015
Q4 2014 Oncothyreon Inc Earnings Release
Mar 4, 2015
Oncothyreon Inc at Cowen Health Care Conference
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -94.40% -55.16%
Return on average equity -105.52% -61.37%
Employees 49 -
CDP Score - -

Address

2601 4th Ave Ste 500
SEATTLE, WA 98121-3222
United States - Map
+1-206-8012100 (Phone)
+1-206-8012101 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Oncothyreon Inc. (Oncothyreon) is a clinical-stage biopharmaceutical company focused primarily on the development of therapeutic products for the treatment of cancer. The Company�s cancer vaccines are designed to stimulate the immune system to attack cancer cells, while its small molecule compounds are designed to inhibit the activity of specific cancer-related proteins. Its lead product candidate, tecemotide (formerly known as L-BLP25 or Stimuvax), is being evaluated for the treatment of non-small cell lung cancer (NSCLC). It has granted worldwide license to Merck KGaA of Darmstadt, Germany (Merck KGaA), for the development, manufacture and commercialization of tecemotide. It is conducting a Phase I trial for ONT-10, a cancer vaccine directed against the same target as tecemotide. It is also collaborating with Array BioPharma Inc. (Array) to develop and commercialize ONT-380, an orally active, reversible and selective small-molecule HER2 inhibitor.

Officers and directors

Robert L. Kirkman M.D. President, Chief Executive Officer, Director
Age: 66
Bio & Compensation  - Reuters
Julia Marie Eastland Chief Financial Officer, Vice President - Corporate Development, Secretary
Age: 49
Bio & Compensation  - Reuters
Gary W Christianson Chief Operating Officer
Age: 60
Bio & Compensation  - Reuters
Jay Venkatesan M.D. Executive Vice President, General Manager
Age: 43
Bio & Compensation  - Reuters
Scott Peterson Ph.D. Chief Scientific Officer
Age: 53
Bio & Compensation  - Reuters
Diana Hausman M.D. Chief Medical Officer
Age: 50
Bio & Compensation  - Reuters
Christopher S. Henney Ph.D. Non-Executive Independent Chairman of the Board
Age: 74
Bio & Compensation  - Reuters
Richard L. Jackson Ph.D. Independent Director
Age: 75
Bio & Compensation  - Reuters
Steven P. James Independent Director
Age: 56
Bio & Compensation  - Reuters
Ted W. Love M.D. Independent Director
Age: 56
Bio & Compensation  - Reuters